MA38090B1 - Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine - Google Patents

Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine

Info

Publication number
MA38090B1
MA38090B1 MA38090A MA38090A MA38090B1 MA 38090 B1 MA38090 B1 MA 38090B1 MA 38090 A MA38090 A MA 38090A MA 38090 A MA38090 A MA 38090A MA 38090 B1 MA38090 B1 MA 38090B1
Authority
MA
Morocco
Prior art keywords
pyridin
fluoro
derivatives
sulfoximine group
amines containing
Prior art date
Application number
MA38090A
Other languages
English (en)
Other versions
MA38090A1 (fr
Inventor
Gerhard Siemeister
Philip Lienau
Ulf Bömer
Ludwig Zorn
Rolf Bohlmann
Ulrich Lücking
Niels Böhnke
Arne Scholz
Dirk Kosemund
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA38090A1 publication Critical patent/MA38090A1/fr
Publication of MA38090B1 publication Critical patent/MA38090B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des dérivés de 5-fluoro-n-(pyridin-2-yl)pyridin-2-amines contenant un groupe sulfoximine de formule générale (i), comme défini et indiqué dans la description; et des méthodes pour les préparer et les utiliser pour le traitement et/ou la prévention de troubles, en particulier de troubles hyperprolifératifs et/ou de maladies infectieuses d'origine virale et/ou de maladies cardiovasculaires. L'invention concerne également des composés intermédiaires utiles pour la préparation des composés de formule générale (i).
MA38090A 2012-11-15 2013-11-12 Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine MA38090B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12192852 2012-11-15
PCT/EP2013/073637 WO2014076091A1 (fr) 2012-11-15 2013-11-12 Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine

Publications (2)

Publication Number Publication Date
MA38090A1 MA38090A1 (fr) 2018-02-28
MA38090B1 true MA38090B1 (fr) 2018-09-28

Family

ID=47148672

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38090A MA38090B1 (fr) 2012-11-15 2013-11-12 Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine

Country Status (42)

Country Link
US (2) US9650340B2 (fr)
EP (1) EP2928878B1 (fr)
JP (1) JP6263193B2 (fr)
KR (1) KR102242871B1 (fr)
CN (1) CN105102444B (fr)
AP (1) AP3872A (fr)
AR (1) AR093505A1 (fr)
AU (1) AU2013346939B2 (fr)
BR (1) BR112015010707B1 (fr)
CA (1) CA2891358C (fr)
CL (1) CL2015001304A1 (fr)
CR (1) CR20150256A (fr)
CU (1) CU20150052A7 (fr)
CY (1) CY1118441T1 (fr)
DK (1) DK2928878T3 (fr)
DO (1) DOP2015000118A (fr)
EA (1) EA027226B1 (fr)
EC (1) ECSP15019323A (fr)
ES (1) ES2612978T3 (fr)
HR (1) HRP20161547T1 (fr)
HU (1) HUE032868T2 (fr)
IL (1) IL238322A (fr)
JO (1) JO3332B1 (fr)
LT (1) LT2928878T (fr)
MA (1) MA38090B1 (fr)
ME (1) ME02880B (fr)
MX (1) MX374333B (fr)
MY (1) MY170609A (fr)
NZ (1) NZ707084A (fr)
PE (1) PE20151071A1 (fr)
PH (1) PH12015501003B1 (fr)
PL (1) PL2928878T3 (fr)
PT (1) PT2928878T (fr)
RS (1) RS55580B1 (fr)
SG (1) SG11201503079PA (fr)
SI (1) SI2928878T1 (fr)
SV (1) SV2015004979A (fr)
TN (1) TN2015000185A1 (fr)
TW (1) TWI613193B (fr)
UA (1) UA115254C2 (fr)
UY (1) UY35141A (fr)
WO (1) WO2014076091A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
HK1209414A1 (en) 2012-10-18 2016-04-01 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
JP6277196B2 (ja) 2012-10-18 2018-02-07 バイエル ファーマ アクチエンゲゼルシャフト スルホン基を含んでいるｎ−（ピリジン−２−イル）ピリミジン−４−アミン誘導体
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
MA38090B1 (fr) 2012-11-15 2018-09-28 Bayer Pharma AG Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine
CN108658876A (zh) 2012-12-17 2018-10-16 帕里昂科学公司 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
CA2895512C (fr) 2012-12-17 2021-10-19 Parion Sciences, Inc. Derives de chloro-pyrazine carboxamide utiles dans le traitement de maladies favorisees par une hydratation insuffisante des muqueuses
CN105492438B (zh) * 2013-07-04 2018-08-07 拜耳医药股份有限公司 磺亚胺取代的5-氟-n-(吡啶-2-基)吡啶-2-胺衍生物以及其作为cdk9激酶抑制剂的用途
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US9856242B2 (en) 2014-03-13 2018-01-02 Bayer Pharma Aktiengesellscaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
US9790189B2 (en) 2014-04-01 2017-10-17 Bayer Pharma Aktiengesellschaft Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
TN2016000435A1 (en) 2014-04-11 2018-04-04 Bayer Pharma AG Novel macrocyclic compounds.
WO2016059011A1 (fr) 2014-10-16 2016-04-21 Bayer Pharma Aktiengesellschaft Dérivés de benzofuranyle-pyrimidine fluorés contenant un groupe sulfone
EP3207038B1 (fr) 2014-10-16 2018-08-22 Bayer Pharma Aktiengesellschaft Dérivés de benzofuranyle-pyrimidine fluorés contenant un groupe sulfoximine
US10717749B2 (en) 2015-09-29 2020-07-21 Bayer Pharma Aktiengesellschaft Macrocyclic sulfondiimine compounds
JP6888000B2 (ja) 2015-10-08 2021-06-16 バイエル ファーマ アクチエンゲゼルシャフト 新規な修飾された大環状化合物
WO2017060322A2 (fr) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Conjugué anticorps-médicament (adc) inhibiteur de ptefb
EP3601253B1 (fr) 2017-03-28 2021-09-15 Bayer Aktiengesellschaft Nouveaux composés macrocycliques inhibiteurs de ptefb
CA3057891A1 (fr) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Nouveaux composes macrocycliques inhibiteurs de ptefb
MA51820A (fr) * 2018-02-13 2021-05-19 Bayer Ag Utilisation de 5-fluoro-4-(4-fluoro-2-méthoxyphényl)-n-(4-[(s-méthylsulfonimidoyl)méthyl]pyridin-2-yl)pyridin-2-amine pour traiter un lymphome diffus à grandes cellules b
AU2020401999B2 (en) 2019-12-09 2024-01-18 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Compound as cyclin-dependent kinase 9 inhibitor and use thereof
US20230106032A1 (en) * 2020-03-06 2023-04-06 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
CN116249701B (zh) * 2020-10-12 2025-05-30 上海海雁医药科技有限公司 取代的二（吡啶-2-基）胺衍生物、其组合物及医药上的用途
CN117015539A (zh) * 2022-03-25 2023-11-07 成都苑东生物制药股份有限公司 一种氨基吡啶类衍生物、其制备方法及用途
WO2024044757A1 (fr) * 2022-08-26 2024-02-29 Sanford Burnham Prebys Medical Discovery Institute Dérivés d'aminopyrimidine et d'aminotriazine utilisés en tant que modulateurs de la protéine myc
KR20250127261A (ko) * 2022-11-02 2025-08-26 빈서스 파마, 인코포레이티드 암에 대한 cdk9 억제제를 포함하는 병용 요법
WO2024112656A1 (fr) * 2022-11-21 2024-05-30 The Board Of Trustees Of The Leland Stanford Junior University Utilisation d'un inhibiteur de tyrosine kinase pour le traitement de la télangiectasie hémorragique héréditaire et de l'hypertension artérielle pulmonaire

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1343782B1 (fr) 2000-12-21 2009-05-06 SmithKline Beecham Corporation Composes chimiques
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
NZ555474A (en) 2004-12-17 2010-10-29 Astrazeneca Ab 4-(4-(imidazol-4-yl) pyrimidin-2-ylamino) benzamides as CDK inhibitors
DE102006041382A1 (de) * 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
WO2008060248A1 (fr) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Pyrimidines substituées par indole, et leur utilisation dans le traitement d'un cancer
CA2672518A1 (fr) 2006-12-22 2008-07-03 Novartis Ag Composes organiques et leurs utilisations
JP2010514688A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー インドール−４−イルピリミジニル−２−イル−アミン誘導体およびサイクリン依存性キナーゼ阻害剤としてのその使用
WO2008129070A1 (fr) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibiteurs de protéines kinases
JP5566880B2 (ja) * 2007-04-24 2014-08-06 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤としての４，６−二置換アミノピリミジン誘導体
WO2008129071A1 (fr) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibiteurs des protéines kinases
WO2008132138A1 (fr) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Dérivés d'aminopyrimidines disubstituées en 4 et en 6
WO2009029998A1 (fr) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Composés rétrométaboliques
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
EA026917B1 (ru) 2010-03-22 2017-05-31 Лид Дискавери Сентр Гмбх Фармацевтически активные производные двузамещенного триазина
WO2012101063A1 (fr) * 2011-01-28 2012-08-02 Novartis Ag Composés de n-acyl pyridine biaryl et leurs utilisations
EP2681193B1 (fr) * 2011-03-02 2016-01-06 Lead Discovery Center GmbH Dérivés de pyridine disubstitués pharmaceutiquement actifs
EP2527332A1 (fr) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phényl-1,3,5-triazin-2-amines portant un groupe sulfoximine en tant qu'inhibiteurs de CDK9
WO2013037896A1 (fr) 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh 5-fluoropyrimidines disubstituées
EP2755948B1 (fr) 2011-09-16 2016-05-25 Bayer Intellectual Property GmbH Dérivés de 5-fluoropyrimidine disubstitués contenant un groupe sulfoximine
HK1209414A1 (en) * 2012-10-18 2016-04-01 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
CN105102434A (zh) 2012-10-18 2015-11-25 拜耳药业股份公司 含砜基团的4-(邻)-氟苯基-5-氟嘧啶-2-基胺
JP6300818B2 (ja) 2012-11-15 2018-03-28 バイエル ファーマ アクチエンゲゼルシャフト スルホキシイミン基を含有する４−（オルト）−フルオロフェニル−５−フルオロピリミジン−２−イルアミン
MA38090B1 (fr) 2012-11-15 2018-09-28 Bayer Pharma AG Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine
CN105492438B (zh) 2013-07-04 2018-08-07 拜耳医药股份有限公司 磺亚胺取代的5-氟-n-(吡啶-2-基)吡啶-2-胺衍生物以及其作为cdk9激酶抑制剂的用途
US9856242B2 (en) 2014-03-13 2018-01-02 Bayer Pharma Aktiengesellscaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group

Also Published As

Publication number Publication date
IL238322A (en) 2017-08-31
HRP20161547T1 (hr) 2016-12-30
HK1213255A1 (zh) 2016-06-30
CN105102444A (zh) 2015-11-25
IL238322A0 (en) 2015-06-30
US9650340B2 (en) 2017-05-16
EP2928878B1 (fr) 2016-11-02
SG11201503079PA (en) 2015-06-29
ES2612978T3 (es) 2017-05-19
AR093505A1 (es) 2015-06-10
ECSP15019323A (es) 2016-01-29
TWI613193B (zh) 2018-02-01
MX374333B (es) 2025-03-06
CY1118441T1 (el) 2017-06-28
JO3332B1 (ar) 2019-03-13
KR20150084968A (ko) 2015-07-22
US20170202815A1 (en) 2017-07-20
CN105102444B (zh) 2017-08-01
AP2015008432A0 (en) 2015-05-31
ME02880B (fr) 2018-04-20
WO2014076091A1 (fr) 2014-05-22
CA2891358A1 (fr) 2014-05-22
HUE032868T2 (en) 2017-11-28
PT2928878T (pt) 2017-02-08
CR20150256A (es) 2015-07-01
DK2928878T3 (en) 2016-12-19
KR102242871B1 (ko) 2021-04-20
EA027226B1 (ru) 2017-07-31
NZ707084A (en) 2019-09-27
EP2928878A1 (fr) 2015-10-14
UA115254C2 (uk) 2017-10-10
UY35141A (es) 2014-06-30
JP2015537015A (ja) 2015-12-24
PH12015501003B1 (en) 2017-10-20
PL2928878T3 (pl) 2017-04-28
DOP2015000118A (es) 2015-06-15
SV2015004979A (es) 2017-01-30
CA2891358C (fr) 2021-05-18
TW201420569A (zh) 2014-06-01
BR112015010707A2 (pt) 2017-07-11
SI2928878T1 (sl) 2016-12-30
RS55580B1 (sr) 2017-06-30
BR112015010707A8 (pt) 2019-10-01
AU2013346939A1 (en) 2015-05-14
MY170609A (en) 2019-08-20
LT2928878T (lt) 2016-11-25
US20150291528A1 (en) 2015-10-15
PH12015501003A1 (en) 2015-07-27
BR112015010707B1 (pt) 2022-05-17
JP6263193B2 (ja) 2018-01-17
AP3872A (en) 2016-10-31
CU20150052A7 (es) 2015-09-29
AU2013346939B2 (en) 2017-06-08
MX2015006169A (es) 2015-08-10
EA201590890A1 (ru) 2015-11-30
TN2015000185A1 (en) 2016-10-03
US9877954B2 (en) 2018-01-30
MA38090A1 (fr) 2018-02-28
PE20151071A1 (es) 2015-08-19
CL2015001304A1 (es) 2015-07-17

Similar Documents

Publication Publication Date Title
MA38090B1 (fr) Dérivés de 5-fluoro-n-(pyridin -2-yl)pyridin-2-amines contenant un groupe sulfoximine
MA38091A2 (fr) Dérivés n-(pyridin-2-yl)pyrimidin-4-amines contenant un groupe sulfoximine
MA35132B1 (fr) 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes
MA35039B1 (fr) Dérivés ramifiés de l'acide 3-phénylpropionique et leur utilisation
MA37519B1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MA33509B1 (fr) Dérivés de l'oxazine et leur utilisation dans le traitement de troubles neurologiques
FR2986002A1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA37942A2 (fr) Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
MA34397B1 (fr) Dérivés d'acide napht-2-ylacétique dans le traitement du sida
MA35444B1 (fr) Ligands du récepteur ep1
MA34727B1 (fr) Imidazolylimidazoles condensés utilisés comme composés antiviraux
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
PH12013501089A1 (en) Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
FR3041639B1 (fr) NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
ATE554076T1 (de) Sulfoximinsubstituierte chinazolinderivate als immunmodulatoren, ihre herstellung und ihre verwendung als medikamente
MA34910B1 (fr) Dérivés de 2-methoxy-pyridin-4-yl
MA35102B1 (fr) Dérivés d'acide 7-(hétéroaryl-amino)-6,7,8,9-tétrahydropyrido[1,2-a]indolacétique et leur utilisation en tant que modulateurs du récepteur aux prostaglandines d2
TN2012000166A1 (fr) NOUVEAUX DERIVES (HETEROCYCLE-TETRAHYDRO-PYRIDINE)-(PIPERAZINYL)-1-ALCANONE ET (HETEROCYCLE-DIHYDRO-PYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75
MA37999B1 (fr) Dérivés de macrolide, leur préparation et leur utilisation thérapeutique